Sponsors
The bill improves the ability of law enforcement and public-health agencies to identify, coordinate against, and educate about counterfeit fentanyl/methamphetamine — potentially reducing overdoses — but creates legal ambiguities, civil‑liberties risks, and new costs and administrative burdens for businesses, agencies, and communities.
Consumers, law enforcement, and public-health responders get clearer statutory labeling that lets authorities identify and prosecute products that secretly contain fentanyl or methamphetamine as "counterfeit fentanyl or methamphetamine substance," improving enforcement clarity.
Local public-health responders and law enforcement can more effectively target and remove mislabeled, dangerous drugs from circulation, which may reduce overdoses and acute poisonings.
Children, teens, parents, and communities benefit from more targeted prevention education and more data-driven public-awareness campaigns (e.g., audited 'One Pill Can Kill' efforts), which can increase campaign effectiveness and reduce accidental poisonings.
Consumers, defendants, and contractors face legal ambiguity and potential due-process or enforcement risks because missing or broadly written amendment language could be applied unevenly or expanded in scope.
Communities—particularly marginalized or overpoliced populations—may experience increased policing, investigations, and seizures as emphasis shifts toward enforcement, raising civil‑liberties and justice concerns.
Taxpayers and frontline agencies could face higher costs because implementing, auditing, and reporting on campaigns and data collection imposes administrative burdens that may divert resources from operations.
Based on analysis of 5 sections of legislative text.
Directs DEA to issue a 180-day operational plan on counterfeit fentanyl/methamphetamine pills and requires annual DOJ/DEA/ONDCP reports on seizures, composition, and prosecutions.
Introduced March 19, 2026 by Gabe Evans · Last progress March 19, 2026
Requires federal drug enforcement and justice agencies to treat pills that contain fentanyl, fentanyl analogues, or methamphetamine and that mimic other products as a distinct threat: the DEA must issue an operational response plan within 180 days addressing seizures, investigations, and prevention (with focus on youth awareness) and audit public-awareness campaigns; the DOJ (with DEA and ONDCP) must deliver annual reports to Congress on seizures, composition, charging, and convictions tied to these counterfeit pills. The bill also defines “counterfeit fentanyl or methamphetamine substance” and contains an attempted but incomplete amendment to existing Controlled Substances Act language, leaving one legal change unclear.